Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

Tahapan Penelitian : Complete

Sponsor:

Mitra Pelaksana:

PT Tigermed Consulting Indonesia

No Registry

INA-P0HETP2

Tanggal Input Registry : 19-07-2024

Tracking Information
Tanggal Antisipasi Studi	01-01-2021
Outcome Primer	not specified
Outcome Skunder

Descriptive Information
Judul Penelitian Popular	Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Judul Penelitian Ilmiah	Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Jenis Penelitian	Interventional
Intervensi	SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine
Jumlah Subyek Penelitian	5

Recruitment Information
Eligibility Criteria	Inclusion Criteria: not specified Exclusion Criteria: not specified

Administrative Information
Nomor Persetujuan Etik	not specified
Nomor Persetujuan Material Transfer Agreement	Not applicable
Nomor Persetujuan Pelaksanaan Uji Klinik	PPUK/PPUB number
Other Study ID Numbers
Contact Person	not specified